University of Pennsylvania

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1740-11-14

Employees: 5K

Market Cap: -

Website: http://www.upenn.edu

Clinical Trials

Effects of Nicotine on Brain Opioid Receptors

Terminated

Conditions: Nicotine Dependence

Interventions: Drug: Nicotine

First Posted Date: 2009-12-29

Last Posted Date: 2019-04-11

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 15

Registration Number: NCT01040338

Locations: 🇺🇸
Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome

Phase 4

Completed

Conditions: Major Depressive Disorder
Pain
Soft Tissue Discomfort Syndrome

Interventions: Drug: Duloxetine

First Posted Date: 2009-12-18

Last Posted Date: 2020-04-16

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 22

Registration Number: NCT01035073

Locations: 🇺🇸
Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States

Adaptive Treatment for Alcohol and Cocaine Dependence

Phase 2

Completed

Conditions: Substance Use Disorders

Interventions: Behavioral: Motivational Interviewing
Behavioral: Telephone counseling
Behavioral: Cognitive Behavioral Therapy (CBT) Counseling
Drug: medication management
Behavioral: Intensive OutPatient Therapy

First Posted Date: 2009-12-15

Last Posted Date: 2017-09-05

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 500

Registration Number: NCT01032135

Locations: 🇺🇸
Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
VAMC, Philadelphia, Pennsylvania, United States
🇺🇸
NorthEast Treatment Center, Philadelphia, Pennsylvania, United States

BMS Reverse Cholesterol Transport (RCT) Study

Not Applicable

Completed

Conditions: Healthy

Interventions: Other: 3H-Cholesterol

First Posted Date: 2009-12-15

Last Posted Date: 2018-12-19

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 12

Registration Number: NCT01031862

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Reverse Cholesterol Transport (RCT) Study

Not Applicable

Completed

Conditions: Healthy

Interventions: Other: 3H-Cholesterol

First Posted Date: 2009-12-15

Last Posted Date: 2018-12-20

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 18

Registration Number: NCT01031758

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Patent Ductus Arteriosus (PDA) Screening Trial

Not Applicable

Completed

Conditions: Ductus Arteriosus, Patent

Interventions: Other: Nondisclosure of screening echocardiogram results
Other: Disclosure of screening echocardiogram results

First Posted Date: 2009-12-14

Last Posted Date: 2014-01-03

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 88

Registration Number: NCT01031316

Locations: 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

Phase 1

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Recurrent Grade 2 Follicular Lymphoma
Stage III Mantle Cell Lymphoma
Hematopoietic/Lymphoid Cancer
B-cell Chronic Lymphocytic Leukemia
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage III Grade 1 Follicular Lymphoma

Interventions: Biological: CART-19

First Posted Date: 2009-12-10

Last Posted Date: 2023-06-22

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 26

Registration Number: NCT01029366

Locations: 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States

Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant

Phase 2

Terminated

Conditions: Desensitization

Interventions: Drug: Belimumab

First Posted Date: 2009-12-03

Last Posted Date: 2017-06-12

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 8

Registration Number: NCT01025193

Locations: 🇺🇸
University of Pennsyvlania Kidney Transplant Program, Philadelphia, Pennsylvania, United States

CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: Infusion of CD3/CD28 stimulated T cells

First Posted Date: 2009-11-13

Last Posted Date: 2019-10-23

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 20

Registration Number: NCT01013441

Locations: 🇺🇸
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center, University of Texas, Houston, Texas, United States

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients

Phase 1

Completed

Conditions: HIV-1 Infections

Interventions: Biological: T cells
Drug: HAART

First Posted Date: 2009-11-13

Last Posted Date: 2022-08-19

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 17

Registration Number: NCT01013415

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy